Mammalian ANP32A and ANP32B Proteins Drive Differential Polymerase Adaptations in Avian Influenza Virus.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
31 05 2023
Historique:
medline: 2 6 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

ANP32 proteins, which act as influenza polymerase cofactors, vary between birds and mammals. In mammals, ANP32A and ANP32B have been reported to serve essential but redundant roles to support influenza polymerase activity. The well-known mammalian adaptation PB2-E627K enables influenza polymerase to use mammalian ANP32 proteins. However, some mammalian-adapted influenza viruses do not harbor this substitution. Here, we show that alternative PB2 adaptations, Q591R and D701N, also allow influenza polymerase to use mammalian ANP32 proteins, whereas other PB2 mutations, G158E, T271A, and D740N, increase polymerase activity in the presence of avian ANP32 proteins as well. Furthermore, PB2-E627K strongly favors use of mammalian ANP32B proteins, whereas D701N shows no such bias. Accordingly, PB2-E627K adaptation emerges in species with strong pro-viral ANP32B proteins, such as humans and mice, while D701N is more commonly seen in isolates from swine, dogs, and horses, where ANP32A proteins are the preferred cofactor. Using an experimental evolution approach, we show that the passage of viruses containing avian polymerases in human cells drove acquisition of PB2-E627K, but not in the absence of ANP32B. Finally, we show that the strong pro-viral support of ANP32B for PB2-E627K maps to the low-complexity acidic region (LCAR) tail of ANP32B.

Identifiants

pubmed: 37074204
doi: 10.1128/jvi.00213-23
pmc: PMC10231198
mid: EMS173956
doi:

Substances chimiques

ANP32A protein, human 0
ANP32B protein, human 0
Anp32b protein, mouse 0
Cell Cycle Proteins 0
Nerve Tissue Proteins 0
Nuclear Proteins 0
Nucleotidyltransferases EC 2.7.7.-
RNA-Binding Proteins 0
RNA-Dependent RNA Polymerase EC 2.7.7.48
Viral Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0021323

Subventions

Organisme : Wellcome Trust
ID : 205100
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/K002465/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200187
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/K002465/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S008292/1
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Nat Commun. 2011 Jan 18;2:156
pubmed: 21245837
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11175-80
pubmed: 25024224
J Virol. 2012 Jan;86(2):1233-7
pubmed: 22072752
Cell Host Microbe. 2008 Aug 14;4(2):111-22
pubmed: 18692771
Nat Rev Microbiol. 2019 Jan;17(2):67-81
pubmed: 30487536
Front Immunol. 2020 Mar 13;11:450
pubmed: 32231671
mBio. 2023 Feb 28;14(1):e0339922
pubmed: 36645303
PLoS Pathog. 2020 Feb 21;16(2):e1008330
pubmed: 32084248
J Virol. 2010 Oct;84(19):9978-86
pubmed: 20631125
J Virol. 1993 Apr;67(4):1761-4
pubmed: 8445709
J Virol. 2019 Aug 13;93(17):
pubmed: 31217244
Eur J Cell Biol. 2015 Jul-Sep;94(7-9):368-74
pubmed: 26074198
J Virol. 2022 Feb 23;96(4):e0209221
pubmed: 34935435
Elife. 2019 Jun 04;8:
pubmed: 31159925
J Virol. 2013 Jan;87(2):1278-84
pubmed: 23115299
Elife. 2015 Oct 29;4:
pubmed: 26512887
J Virol. 2013 Jan;87(1):384-94
pubmed: 23077313
J Virol. 2020 Jun 1;94(12):
pubmed: 32269123
Nature. 2020 Nov;587(7835):638-643
pubmed: 33208942
Nature. 2016 Jan 7;529(7584):101-4
pubmed: 26738596
Nat Commun. 2020 Jul 21;11(1):3656
pubmed: 32694517
Int J Mol Sci. 2017 Dec 13;18(12):
pubmed: 29236050
J Virol. 2014 Nov;88(22):13269-83
pubmed: 25210166
Annu Rev Virol. 2019 Sep 29;6(1):215-233
pubmed: 31283439
Cell Rep. 2018 Sep 4;24(10):2581-2588.e4
pubmed: 30184493
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21312-6
pubmed: 19995968
J Virol. 2013 Sep;87(18):9983-96
pubmed: 23843645
J Virol. 2019 Jun 14;93(13):
pubmed: 30996088
Nat Commun. 2019 Jul 30;10(1):3396
pubmed: 31363119
J Virol. 2020 Jan 17;94(3):
pubmed: 31694956

Auteurs

Thomas P Peacock (TP)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Carol M Sheppard (CM)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Margaret G Lister (MG)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Ecco Staller (E)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Rebecca Frise (R)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Olivia C Swann (OC)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Daniel H Goldhill (DH)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Jason S Long (JS)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Wendy S Barclay (WS)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH